# Gene Therapy: Rewriting the Human Operating System

## Overview

Gene therapy in 2200 is not a medical intervention — it's a consumer product. The ability to modify human DNA in vivo (in a living person) or in vitro (in embryonic cells before birth) has matured from experimental treatment to routine service. Sterling-Nakamura's genetic optimization division processes 200,000 gene therapy procedures annually in GLMZ alone, ranging from targeted disease corrections to comprehensive genetic optimization packages that reshape a person's biology from the genome up.

## Capability Spectrum

### Therapeutic Gene Therapy
The correction of genetic defects that cause disease. This is the oldest and most established form of gene therapy: replacing a faulty gene with a functional copy to cure conditions like cystic fibrosis, sickle cell disease, and hereditary cancer predispositions. Therapeutic gene therapy is covered by all corporate medical plans and available through UBC medical allocation for acute conditions. Cost: Φ500-5,000 per condition treated.

### Enhancement Gene Therapy
The modification of functional genes to improve performance beyond baseline human capabilities. This includes: increased muscle density, improved cardiovascular efficiency, enhanced sensory acuity, accelerated wound healing, and optimized metabolic function. Enhancement therapy is not covered by UBC — it's a consumer product priced at Φ5,000-50,000 depending on the scope of modification.

### Comprehensive Genetic Optimization
A package of modifications applied in utero or in early childhood that optimizes every system in the body: musculoskeletal, cardiovascular, neurological, immune, metabolic, and endocrine. A genetically optimized child will be taller, stronger, healthier, more disease-resistant, more cognitively capable, and longer-lived than an unoptimized child. The optimization doesn't create superhumans — it moves every parameter to the top of the normal human range. Cost: Φ50,000-200,000 per child. Available only to families that can afford it, which means available only to the corporate class.

## The Genetic Divide

Comprehensive genetic optimization is creating a biological class divide. Children born into wealthy families are genetically optimized; children born into poor families are not. Over three generations, this has produced measurable population-level differences between the optimized and unoptimized: 8-12% differences in cognitive test scores, 15-20% differences in disease rates, and a projected 15-20 year difference in healthy lifespan.

The optimized don't think of themselves as a separate species — but the unoptimized are beginning to. The term "geneborn" (optimized from conception) versus "wildtype" (unmodified) has entered common usage. The distinction carries class implications that are explicitly biological: you can see the difference. Geneborn children are taller, healthier, and more symmetrical than their wildtype peers. The difference is subtle but cumulative, and it compounds across generations.

## Regulation

Gene therapy is regulated by the Biological Modification Ethics Charter — an agreement between all six corponations that prohibits modifications beyond "the enhancement of existing human biological parameters." This language is deliberately vague. It prohibits creating humans with four arms or gills. It does not prohibit making every existing parameter as good as it can be. The Charter's vagueness is the legal space in which the genetic divide grows.

Elena Vasquez-9 and Nia Okafor-Bright have both spoken publicly about the genetic divide as a rights issue — arguing that access to genetic optimization should be universal rather than wealth-dependent. Their advocacy has produced no policy change. The corponations that fund genetic optimization are the same corponations that govern the city. They see no reason to provide their competitive advantage to everyone.